Chris A. Rallis - 19 May 2023 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A Rallis
Issuer symbol
FENC
Transactions as of
19 May 2023
Net transactions value
-$12,939
Form type
4
Filing time
19 May 2023, 16:41:58 UTC
Previous filing
17 Apr 2023
Next filing
13 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Sale $6,131 -833 -2.5% $7.36 31,958 19 May 2023 Direct F1
transaction FENC Common Shares Sale $6,808 -925 -2.9% $7.36 31,033 19 May 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale of common shares sold in accordance with 10b5-1 plan. Commom shares resulted from exercise of option grant with grant date of 4/4/2012.
F2 Sale of common shares sold in accordance with 10b5-1 plan. Commom shares resulted from exercise of option grant with grant date of 5/17/2012.